GSK will price vaccine responsibly: Emmanuel Hanon, R&D Head

GSK said it was not expecting to profit from its collaborations on a vaccine candidate during the pandemic as the company rushes to offer 1 billion doses by next year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dQ0G5W
via IFTTT